GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Elanix Biotechnologies AG (FRA:ELN) » Definitions » Beneish M-Score

Elanix Biotechnologies AG (FRA:ELN) Beneish M-Score : 0.00 (As of May. 30, 2024)


View and export this data going back to . Start your Free Trial

What is Elanix Biotechnologies AG Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

The historical rank and industry rank for Elanix Biotechnologies AG's Beneish M-Score or its related term are showing as below:

During the past 11 years, the highest Beneish M-Score of Elanix Biotechnologies AG was 0.00. The lowest was 0.00. And the median was 0.00.


Elanix Biotechnologies AG Beneish M-Score Historical Data

The historical data trend for Elanix Biotechnologies AG's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Elanix Biotechnologies AG Beneish M-Score Chart

Elanix Biotechnologies AG Annual Data
Trend Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - 27.64 -10.26

Elanix Biotechnologies AG Semi-Annual Data
Dec08 Dec09 Jun10 Dec10 Jun11 Dec11 Jun12 Dec12 Jun13 Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - 27.64 - -10.26

Competitive Comparison of Elanix Biotechnologies AG's Beneish M-Score

For the Drug Manufacturers - Specialty & Generic subindustry, Elanix Biotechnologies AG's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Elanix Biotechnologies AG's Beneish M-Score Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Elanix Biotechnologies AG's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Elanix Biotechnologies AG's Beneish M-Score falls into.



Elanix Biotechnologies AG Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Elanix Biotechnologies AG for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 2.5678+0.528 * -0.106+0.404 * 0.7803+0.892 * 0.2731+0.115 * 0.7633
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 2.5719+4.679 * -1.093692-0.327 * 3.0006
=-8.43

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec18) TTM:Last Year (Dec17) TTM:
Total Receivables was €0.63 Mil.
Revenue was €0.06 Mil.
Gross Profit was €-0.22 Mil.
Total Current Assets was €0.65 Mil.
Total Assets was €1.08 Mil.
Property, Plant and Equipment(Net PPE) was €0.03 Mil.
Depreciation, Depletion and Amortization(DDA) was €0.01 Mil.
Selling, General, & Admin. Expense(SGA) was €1.41 Mil.
Total Current Liabilities was €2.31 Mil.
Long-Term Debt & Capital Lease Obligation was €0.00 Mil.
Net Income was €-3.73 Mil.
Gross Profit was €0.00 Mil.
Cash Flow from Operations was €-2.55 Mil.
Total Receivables was €0.90 Mil.
Revenue was €0.23 Mil.
Gross Profit was €0.09 Mil.
Total Current Assets was €1.27 Mil.
Total Assets was €2.47 Mil.
Property, Plant and Equipment(Net PPE) was €0.04 Mil.
Depreciation, Depletion and Amortization(DDA) was €0.01 Mil.
Selling, General, & Admin. Expense(SGA) was €2.00 Mil.
Total Current Liabilities was €1.76 Mil.
Long-Term Debt & Capital Lease Obligation was €0.00 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(0.634 / 0.062) / (0.904 / 0.227)
=10.225806 / 3.982379
=2.5678

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(0.085 / 0.227) / (-0.219 / 0.062)
=0.374449 / -3.532258
=-0.106

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (0.654 + 0.03) / 1.078) / (1 - (1.271 + 0.04) / 2.466)
=0.365492 / 0.46837
=0.7803

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=0.062 / 0.227
=0.2731

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(0.012 / (0.012 + 0.04)) / (0.013 / (0.013 + 0.03))
=0.230769 / 0.302326
=0.7633

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(1.407 / 0.062) / (2.003 / 0.227)
=22.693548 / 8.823789
=2.5719

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((0 + 2.306) / 1.078) / ((0 + 1.758) / 2.466)
=2.139147 / 0.712895
=3.0006

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-3.73 - 0 - -2.551) / 1.078
=-1.093692

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Elanix Biotechnologies AG has a M-score of -8.43 suggests that the company is unlikely to be a manipulator.


Elanix Biotechnologies AG Beneish M-Score Related Terms

Thank you for viewing the detailed overview of Elanix Biotechnologies AG's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Elanix Biotechnologies AG (FRA:ELN) Business Description

Traded in Other Exchanges
N/A
Address
Street-4, Georg-Glock, c/o HEUKING KÜHN LÜER WOJTEK, Dusseldorf, NW, DEU, 40474
Elanix Biotechnologies AG is a tissue regeneration company. It develops and commercializes products for acute wound care, dermatological and gynecological applications as well as providing cell technology services. The company's operating segment include Regenerative Medicine and Cosmetic ointments. It generates maximum revenue from the Cosmetic ointments segment. Geographically, it derives a majority of revenue from Switzerland and also has a presence in the EU, and Taiwan.

Elanix Biotechnologies AG (FRA:ELN) Headlines

No Headlines